Eagle Pharmaceuticals, Inc. is a biotechnology pharmaceutical company, which focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. The company is headquartered in Woodcliff Lake, New Jersey and currently employs 134 full-time employees. The company went IPO on 2014-02-12. The firm is focused on developing medicines that result in improvements in patients' lives. The firm's commercialized products include vasopressin, PEMFEXY, RYANODEX, BENDEKA, BELRAPZO, TREAKISYM (Japan), and BYFAVO and BARHEMSYS through its wholly owned subsidiary Acacia Pharma Inc. Its oncology and central nervous system (CNS)/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. The firm also has a research and development facility in Cambridge, Massachusetts. The firm is also focused on developing medicines with the potential to become part of the personalized medicine paradigm in cancer care. The firm has office space in Palm Beach Gardens, Florida and Indianapolis, Indiana.
Follow-Up Questions
¿Cuál es el ratio P/E de Eagle Pharmaceuticals Inc (EGRX)?
El ratio P/E de Eagle Pharmaceuticals Inc es 1.2294
¿Qué tal es el rendimiento del precio de la acción EGRX?
El precio actual de EGRX es de $1.5, ha decreased un 0% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Eagle Pharmaceuticals Inc?
Eagle Pharmaceuticals Inc pertenece a la industria Biotechnology y el sector es Health Care
¿Cuál es la capitalización bursátil de Eagle Pharmaceuticals Inc?
La capitalización bursátil actual de Eagle Pharmaceuticals Inc es $19.4M
¿Es Eagle Pharmaceuticals Inc una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 3 analistas han realizado calificaciones de análisis para Eagle Pharmaceuticals Inc, incluyendo 3 fuerte compra, 3 compra, 1 mantener, 0 venta, y 3 fuerte venta
